- Pharmacogenetics testing, which involves analyzing how genetic variations affect a patient’s response to psychiatric medications, is becoming an essential tool in personalized mental healthcare. It enables clinicians to make informed decisions about antidepressant prescriptions, improving treatment outcomes and reducing adverse effects in patients with depression and other psychiatric disorders
- The growing demand for pharmacogenetics testing in psychiatry and depression treatment is primarily driven by the rising prevalence of mental health disorders, increasing awareness among healthcare providers about the benefits of personalized medicine, and expanding support from regulatory bodies for genetic-based therapeutic decisions
- North America dominated the pharmacogenetics testing in psychiatry/depression market with the largest revenue share of 40.6% in 2024, owing to the early adoption of precision medicine, favorable reimbursement policies, and strong presence of leading diagnostic companies. The U.S. in particular has witnessed significant uptake in pharmacogenetic testing due to its integration into psychiatric clinical workflows and increasing use by mental health professionals in both private and public healthcare systems
- Asia-Pacific is projected to be the fastest growing region in the pharmacogenetics testing in psychiatry/depression market during the forecast period, expected to grow at a CAGR of 12.9% from 2025 to 2032, driven by increasing urbanization, rising mental health awareness, government support for genomic research, and improvements in healthcare infrastructure across countries such as China, India, and Japan
- The adult segment held the largest market share of 62.1% in 2024 among all patient types, attributed to the high prevalence of psychiatric conditions in the adult population and the widespread use of pharmacogenetic testing to optimize psychiatric medication regimens and improve treatment outcomes
